This inventor holds 42 USPTO granted patents and 4 published patent applications, primarily in Cancer Cell Death. Top assignees: The University of Toledo, American Hospital Supply Corporation, Schering Aktiengesellschaft. Active years: 1983-2025.
Location History:
- Mundelein, IL (US) (1983 - 1986)
- Long Valley, NJ (US) (1985 - 1996)
- Sylvania, OH (US) (1995 - 2013)
- Toledo, OH (US) (2013 - 2024)
Company Filing History:
24 out of 367Â 
8 out of 433Â 
4 out of 1,409Â 
Years Active: 1983-2025
Areas of Expertise:
Title: Paul W. Erhardt: Innovator in Cancer Treatment and Metabolic Bone Disease Therapies
Introduction
Paul W. Erhardt, a distinguished inventor based in Toledo, OH, has made significant contributions to the field of medical science with an impressive portfolio of 41 patents. His innovative work has focused primarily on developing materials and methods aimed at inducing cancer cell death and treating various bone-related diseases.
Latest Patents
Among his latest patents, Erhardt has developed compounds and compositions useful for inducing cancer cell death via methods such as methuosis and autophagy. These compounds feature a 4-pyridyl group linked through a heterocyclic group to various aryl, heteroaryl, aralkyl, or heteroaryl alkyl structures. Additionally, he has explored peroxisome proliferator-activated receptor (PPAR) compounds, which are aimed at treating bone fractures, osteoporosis, and metabolic bone diseases, as well as inducing osteogenesis and chondrogenesis.
Career Highlights
Erhardt has had a remarkable career in research and development. He has been associated with esteemed institutions such as the University of Toledo, where he has contributed to academic advancements and medical research. He also worked with American Hospital Supply Corporation, further extending his impact on healthcare solutions.
Collaborations
Throughout his career, Paul W. Erhardt has collaborated with notable professionals, including Bruce E. Heck and Dong Hyun Kim. These partnerships have facilitated significant advancements in their respective fields, highlighting Erhardt's ability to work effectively within collaborative research environments.
Conclusion
With a robust patent portfolio and impactful collaborations, Paul W. Erhardt has established himself as a leading figure in innovative cancer treatments and therapies for metabolic bone diseases. His contributions not only demonstrate his expertise but also pave the way for future advancements in medical science, ultimately aiming to improve patient outcomes.